Mucoadhesive nanoparticles for prolonged ocular delivery of natamycin: In vitro and pharmacokinetics studies

International Journal of Pharmaceutics
R S BhattaP K Shukla

Abstract

The aim of this study was to prepare natamycin encapsulated lecithin/chitosan mucoadhesive nanoparticles (NPs) for prolonged ocular application. These NPs were characterized by their mean particle size 213nm, encapsulation efficiency 73.57%, with a theoretical drug loading 5.09% and zeta potential +43. In vitro release exhibited a biphasic drug release profile with initial burst followed by a very slow drug release. The MIC(90) and zone of inhibition of NPs showed similar antifungal activity as compared to marketed suspension and free natamycin against Candida albicans and Aspergillus fumigates. The ocular pharmacokinetics of NPs and marketed formulation were evaluated in NZ rabbits. The NPs exhibit significant mucin adhesion. The AUC((0-∞)) was increased up to 1.47 fold and clearance was decreased up to 7.4-fold as compared to marketed suspension. The PK-PD and pharmacokinetic simulation was carried out to estimate optimum dosing regimen for good efficacy. Thus, lecithin/chitosan NPs could be considered useful approach aiming to prolong ocular residence and reduce dosing frequency.

References

Apr 16, 1973·Biochimica Et Biophysica Acta·S Batzri, E D Korn
Jan 1, 1994·Journal of Ocular Pharmacology·A Joshi
Sep 1, 1995·Journal of Medical and Veterinary Mycology : Bi-monthly Publication of the International Society for Human and Animal Mycology·M S Mathews, T Kuriakose
Apr 16, 1998·Progress in Retinal and Eye Research·C L BourlaisR Leverge
Jun 30, 2000·Clinical and Experimental Pharmacology & Physiology·N M Davies
Sep 8, 2000·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·P ChetoniM F Saettone
Jun 27, 2001·Survey of Ophthalmology·K R Wilhelmus
Oct 2, 2001·Journal of Controlled Release : Official Journal of the Controlled Release Society·S KawakamiH Sasaki
Oct 4, 2005·Advanced Drug Delivery Reviews·John D Smart
Mar 28, 2006·Investigative Ophthalmology & Visual Science·Amalia Enríquez de SalamancaMaria José Alonso
Sep 16, 2006·International Journal of Pharmaceutics·F SonvicoP Colombo
Nov 3, 2006·Advanced Drug Delivery Reviews·Yusuf Ali, Kari Lehmussaari
Jul 10, 2007·Current Opinion in Pharmacology·Russell E Lewis
Apr 11, 2008·Mycoses·P K ShuklaG B S Keshava
Apr 1, 2009·Journal of Controlled Release : Official Journal of the Controlled Release Society·Ramesh C NagarwalJ K Pandit
Mar 24, 2010·Journal of Pharmaceutical Sciences·I PepićJ Filipović-Grcić
Jun 7, 2011·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Taís GratieriRenata F V Lopez

❮ Previous
Next ❯

Citations

Feb 22, 2013·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Lilian GonzalezJin-Hong Chang
Jan 30, 2013·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Wanachat ChaiyasanWaree Tiyaboonchai
Nov 28, 2013·International Journal of Pharmaceutics·Joana F FangueiroEliana B Souto
Jun 9, 2014·Materials Science & Engineering. C, Materials for Biological Applications·Betiana FeliceSeeram Ramakrishna
Jan 18, 2016·Colloids and Surfaces. B, Biointerfaces·Yan JiaoGuangxi Zhai
Nov 26, 2015·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Kesinee Netsomboon, Andreas Bernkop-Schnürch
Sep 6, 2015·International Journal of Pharmaceutics·Panoraia I SiafakaDimitrios N Bikiaris
Mar 19, 2014·The Journal of Pharmacy and Pharmacology·Joel G SouzaRenata F V Lopez
Jun 6, 2013·Journal of Biomedical Materials Research. Part a·Jeffrey M HalpernHorst A von Recum
Mar 31, 2016·Nanotoxicology·Neelesh K MehraSrinath Palakurthi
Apr 15, 2015·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Anita HafnerJelena Filipović-Grčić
Apr 20, 2016·Drug Development and Industrial Pharmacy·Burcu DevrimAsuman Bozkır
Sep 2, 2016·AAPS PharmSciTech·Enas AlkhaderClive J Roberts
Jan 9, 2017·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Fernanda C FloresCristiane B Silva
Apr 11, 2017·Advanced Drug Delivery Reviews·Dileep R JanagamTao L Lowe
Aug 4, 2018·International Journal of Molecular Sciences·Ana C MendesIoannis S Chronakis
Nov 28, 2018·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Prit LakhaniSoumyajit Majumdar
Mar 23, 2019·Nanomedicine·Aseel Mahmood Ibrahim Al-MashahedahJagat Rakesh Kanwar
May 18, 2019·Nanomaterials·Blanca Lorenzo-VeigaCarmen Alvarez-Lorenzo
Aug 15, 2019·AAPS PharmSciTech·Tiantian GongLisa C Rohan
Jan 13, 2018·Therapeutic Delivery·Prit LakhaniSoumyajit Majumdar
Jan 24, 2020·Journal of Biomedical Materials Research. Part B, Applied Biomaterials·Juçara R FrancaAndré A G Faraco
May 2, 2020·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Hala Mohammed El-MoftyNancy M Lotfy
Mar 16, 2019·The Journal of Pharmacology and Experimental Therapeutics·Karthik Yadav JangaSoumyajit Majumdar
Aug 23, 2019·Polymers·Courtney LynchViness Pillay
Dec 8, 2019·Scientific Reports·Basanth Babu EedaraShyamal C Das
Mar 5, 2013·Artificial Cells, Nanomedicine, and Biotechnology·Lalit KumarBhuvaneshwar Vaidya
Jan 1, 2013·World Journal of Pharmacology·Ashaben PatelAshim K Mitra
Jul 7, 2020·Journal, Genetic Engineering & Biotechnology·Anupama Ammulu ManneSudhakar Podha
Oct 27, 2015·Daru : Journal of Faculty of Pharmacy, Tehran University of Medical Sciences·Usha Ganganahalli KapanigowdaPrakash Rao Boggarapu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Candidiasis

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Candidiasis (ASM)

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Candida albicans

Candida albicans is an opportunistic, fungal pathogen of humans that frequently causes superficial infections of oral and vaginal mucosal surfaces of debilitated and susceptible individuals. Discover the latest research on Candida albicans here.

Aspergillosis

Aspergillosis is the name given to a wide variety of diseases caused by infection by fungi of the genus Aspergillus. Aspergillosis occurs in chronic or acute forms which are clinically very distinct. Most cases of acute aspergillosis occur in patients with severely compromised immune systems. Chronic colonization or infection can cause complications in people with underlying respiratory illnesses. Discover the latest research on aspergillosis here.

Aspergillosis (ASM)

Aspergillosis is the name given to a wide variety of diseases caused by infection by fungi of the genus Aspergillus. Aspergillosis occurs in chronic or acute forms which are clinically very distinct. Most cases of acute aspergillosis occur in patients with severely compromised immune systems. Chronic colonization or infection can cause complications in people with underlying respiratory illnesses. Discover the latest research on aspergillosis here.